Clal Biotechnology (Israel) Financial Diagnostics

CBI -- Israel Stock  

ILS 288.20  3.40  1.17%

The recent Clal Biotechnology price drops could raise concerns from investors as the firm closed today at a share price of 287.5 on 24015.000 in volume. The company management were unable to exploit market volatilities in February. However, diversifying your overall positions with Clal Biotechnology Industries Ltd can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 2.8154. The current volatility is consistent with the ongoing market swings in February 2019 as well as with Clal Biotechnology unsystematic, company specific events. This diagnostics interface makes it easy to digest most current publicly released information about Clal Biotechnology as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Clal Biotechnology price relationship with some important fundamental indicators such as market cap and management efficiency. Check also Trending Equities.

Clal Biotechnology Note

The company recorded loss per share of 0.44. Clal Biotechnology had not issued any dividends in recent years. Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. Clal Biotechnology operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. For more info on CLAL BIOTECH please contact the company at 972 3 612 1616 or go to http://www.cbi.co.il.

Clal Biotechnology Alerts

Clal Biotechnology is not yet fully synchronised with the market data
Clal Biotechnology generates negative expected return over the last 30 days
The company reported revenue of 10.09M. Net Loss for the year was (67.78M) with profit before overhead, payroll, taxes, and interest of 11.03M.
CLAL BIOTECH has accumulated about 113.93M in cash with (98.26M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.64.

Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 435.44M.

Management Efficiency

Clal Biotechnology has return on total asset (ROA) of (5.85) % which means that it has lost $5.85 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (10.34) % meaning that it generated substantial loss on money invested by shareholders.

Stock Holders for Clal Biotechnology

Clal Biotechnology Technical and Predictive Indicators

Did you try this?

Run Portfolio Anywhere Now

   

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Portfolio Anywhere

Also Currentnly Active

Purchased few shares of
a day ago
Traded for 1231.54
Purchased few shares of
a day ago
Traded for 183.55
Purchased a lot of shares of
a day ago
Traded for 154.59
Check also Trending Equities. Please also try Cryptocurrency Correlation module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins and exchanges.
Search macroaxis.com